PRINCETON, N.J. & TOKYO–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today presented new results from the Phase 3b study (NCT06973577) evaluating centanafadine in adults with attention-deficit/hyperactivity disorder (ADHD) and comorbid anxiety disorders at Psych Congress 2026 in New Orleans. Expanding on positive topline results shared in June, these analyses provide the most comprehensive view to date of centanaf